Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
about
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Umbralisib, a novel PI3Kδ and ...... alation, first-in-human study.
@en
Umbralisib, a novel PI3Kδ and ...... alation, first-in-human study.
@nl
type
label
Umbralisib, a novel PI3Kδ and ...... alation, first-in-human study.
@en
Umbralisib, a novel PI3Kδ and ...... alation, first-in-human study.
@nl
prefLabel
Umbralisib, a novel PI3Kδ and ...... alation, first-in-human study.
@en
Umbralisib, a novel PI3Kδ and ...... alation, first-in-human study.
@nl
P2093
P1433
P1476
Umbralisib, a novel PI3Kδ and ...... alation, first-in-human study.
@en
P2093
Changchun Deng
Danielle M Brander
Hari P Miskin
Howard A Burris
Ian W Flinn
James H Essell
John G Kuhn
Manish R Patel
Martin Gutierrez
Michael S Weiss
P356
10.1016/S1470-2045(18)30082-2
P577
2018-02-20T00:00:00Z